Evaluation of the effect of Montelukast in allergic rhinitis, Evaluation of the effect of neotadine in the treatment of allergic rhinitis

Comparison of the effect of montelukast with the usual dose of twice as much neotadine with intranasal mometasone in allergic rhinitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211205053277N1

Enrollment

Registered

2023-07-31

Start date

2023-05-02

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis. Other allergic rhinitis

Interventions

Intervention 1: The patients in the first group will be treated by mometasone nasal spray with a dose of 100 micrograms (two puffs in each nose) daily for 8 weeks along with 5 mg desloratadine tablets

Eligibility

Sex/Gender

All

Age

6 Years to No maximum

Inclusion criteria

Inclusion criteria: Having moderate to severe allergic rhinitis over 6 years of age having informed consent

Exclusion criteria

Exclusion criteria: Asthma infection and adenoid hypertrophy Patients with chronic diseases Antihistamine use during the last 1 month Systemic or topical corticosteroids History of neotadine allergy

Design outcomes

Primary

Measure	Time frame
Nasal symptom score. Timepoint: before treatment intervention and two months after treatment. Method of measurement: Nasal symptom scoring table.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Niloufar Ghanbari

Tehran University of Medical Sciences

niloufargh67@yahoo.com+98 21 7756 8801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026